Last reviewed · How we verify
Enalapril 10mg
Enalapril 10mg, marketed by Vanderbilt University, is a well-established drug in the cardiovascular segment. The key composition patent is set to expire in 2028, providing a clear period of exclusivity and potential revenue stability. The primary risk lies in the potential increase in generic competition following the patent expiry, which could erode market share and revenue.
At a glance
| Generic name | Enalapril 10mg |
|---|---|
| Sponsor | Vanderbilt University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS) (PHASE2)
- Postpartum Evaluation of Nifedipine and Enalapril for Hypertension (PHASE4)
- Intra-lesional ACE Inhibitor for Treatment of Hypertrophic Scars (PHASE2, PHASE3)
- Phototoxicity of Frequently Prescribed Medicines (NA)
- Prevention of Diabetes and Hypertension (PHASE4)
- Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts (PHASE4)
- NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients (PHASE4)
- Medicine-induced Cardiac Hemodialysis on COVID-19 (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enalapril 10mg CI brief — competitive landscape report
- Enalapril 10mg updates RSS · CI watch RSS
- Vanderbilt University portfolio CI